ESR1 Is Co-Expressed with Closely Adjacent Uncharacterised Genes Spanning a Breast Cancer Susceptibility Locus at 6q25.1
暂无分享,去创建一个
Mitch Dowsett | Helen Anderson | M. Dowsett | Z. Ghazoui | E. López-Knowles | S. Pancholi | A. Leary | S. Drury | Lesley-Ann Martin | A. Dunbier | K. Sidhu | H. Anderson | Ricardo Ribas | Alexandra Leary | Ricardo Ribas | Zara Ghazoui | Sunil Pancholi | Lesley-Ann Martin | Elena Lopez-Knowles | Anita K. Dunbier | Suzanne Drury | Kally Sidhu | L. Martin | Kally Sidhu
[1] M. Martin,et al. Regulation of estrogen receptor-alpha expression by the tumor suppressor gene p53 in MCF-7 cells. , 2004, The Journal of endocrinology.
[2] R. Blamey,et al. Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer. , 1996, European journal of cancer.
[3] J. Foekens,et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.
[4] Zhiyuan Hu,et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Barry Komm,et al. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. , 2003, Endocrinology.
[6] P. Hegde,et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[7] Myles Brown,et al. Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription , 2000, Cell.
[8] M. Dowsett,et al. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. , 2008, Endocrine-related cancer.
[9] J. Bergh,et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] N. N. Available. World medical association declaration of Helsinki , 2000, Chinese Journal of Integrative Medicine.
[11] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[12] Mitch Dowsett,et al. Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer , 2008, Clinical Cancer Research.
[13] E. Levin,et al. Extranuclear steroid receptors: nature and actions. , 2007, Endocrine reviews.
[14] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[15] Michael Jones,et al. Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. , 2011, Journal of the National Cancer Institute.
[16] P. Hall,et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[17] J. Haines,et al. Genome-wide association study identifies a novel breast cancer susceptibility locus at 6q25.1 , 2009, Nature Genetics.
[18] Fei Huang,et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. , 2007, Cancer research.
[19] Pan Du,et al. lumi: a pipeline for processing Illumina microarray , 2008, Bioinform..
[20] Simak Ali,et al. Endocrine-responsive breast cancer and strategies for combating resistance , 2002, Nature Reviews Cancer.
[21] E. Liu,et al. An Oestrogen Receptor α-bound Human Chromatin Interactome , 2009, Nature.
[22] M. Gottardis,et al. Regulation of estrogen receptor expression , 2004, Breast Cancer Research and Treatment.
[23] Hongbing Shen,et al. Replication and functional genomic analyses of the breast cancer susceptibility locus at 6q25.1 generalize its importance in women of chinese, Japanese, and European ancestry. , 2011, Cancer research.
[24] O. Lingjaerde,et al. ESR1 gene amplification in breast cancer: a common phenomenon? , 2008, Nature Genetics.
[25] A. Ashworth,et al. A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines , 2009, Breast Cancer Research and Treatment.
[26] Robert L. Sutherland,et al. Biological determinants of endocrine resistance in breast cancer , 2009, Nature Reviews Cancer.
[27] A. Jemal,et al. Global Cancer Statistics , 2011 .
[28] Mike Clarke,et al. Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[29] I. Amit,et al. Comprehensive mapping of long range interactions reveals folding principles of the human genome , 2011 .
[30] R. Simon,et al. Controlling the number of false discoveries: application to high-dimensional genomic data , 2004 .
[31] Anne Vincent-Salomon,et al. ESR1 gene amplification in breast cancer: a common phenomenon? , 2008, Nature Genetics.
[32] Clement Adebamowo,et al. Ancestry-Shift Refinement Mapping of the C6orf97-ESR1 Breast Cancer Susceptibility Locus , 2010, PLoS genetics.
[33] G. Sauter,et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer , 2007, Nature Genetics.
[34] Clifford A. Meyer,et al. Genome-wide analysis of estrogen receptor binding sites , 2006, Nature Genetics.
[35] Marc E. Lippman,et al. GREB1 is a critical regulator of hormone dependent breast cancer growth , 2005, Breast Cancer Research and Treatment.
[36] Wei Zheng,et al. Alteration at translational but not transcriptional level of transferrin receptor expression following manganese exposure at the blood-CSF barrier in vitro. , 2005, Toxicology and applied pharmacology.
[37] J. Bergh,et al. Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series , 2007, Clinical Cancer Research.
[38] A. Ashworth,et al. Molecular response to aromatase inhibitor treatment in primary breast cancer , 2007, Breast Cancer Research.
[39] Gianluca Bontempi,et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen , 2008, BMC Genomics.
[40] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[41] G. Hampton,et al. Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole , 2007, Pharmacogenetics and genomics.
[42] A. Wakeling,et al. ICI 182,780, a new antioestrogen with clinical potential , 1992, The Journal of Steroid Biochemistry and Molecular Biology.
[43] T. Ichida. World Medical Association declaration of Helsinki , 1991, Gastroenterologia Japonica.
[44] Debashis Ghosh,et al. A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival. , 2008, Neoplasia.
[45] S. Angeloni,et al. Regulation of estrogen receptor-alpha expression in MCF-7 cells by taxol. , 2004, The Journal of endocrinology.
[46] M. Dowsett,et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] Mike Clarke,et al. Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[48] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[49] A. Ashworth,et al. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers , 2010, Breast Cancer Research and Treatment.
[50] Alberto Costa,et al. Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer , 2010, Breast Cancer Research and Treatment.
[51] A. Ashworth,et al. Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast , 2008, The Journal of pathology.
[52] Deborah Hughes,et al. Genome-wide association study identifies five new breast cancer susceptibility loci , 2010, Nature Genetics.
[53] M. Dowsett,et al. Selection of REFERENCE Genes for Normalization of qRT-PCR Data Derived From FFPE Breast Tumors , 2009, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[54] M. Dowsett,et al. Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor–Treated ER-Positive Breast Cancer , 2011, Clinical Cancer Research.
[55] M. Moran,et al. Large-scale mapping of human protein–protein interactions by mass spectrometry , 2007, Molecular systems biology.
[56] M. Dowsett,et al. Enhanced Estrogen Receptor (ER) α, ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen Deprivation* , 2003, Journal of Biological Chemistry.
[57] P. Darbre,et al. Effect of estradiol on human breast cancer cells in culture. , 1983, Cancer research.
[58] G. Lazennec,et al. Characterization of the transcription start point of the trout estrogen receptor-encoding gene: evidence for alternative splicing in the 5' untranslated region. , 1995, Gene.